Complain about a product or service

Researchers Hopeful About New Alzheimer’s Therapy

"Global Epidemic" Feared if Effective Treatment Isn't Developed Soon

June 12, 2007

• Dementia Linked To Obesity • Studies Find Link Between Diabetes and Alzheimer's • Lifestyle Linked to Alzheimer's Onset • Pot Belly in Middle Age Linked to Alzheimer's • 10 Million Boomers Face Alzheimer's • Alzheimer's Risk Higher in Victims' Children • Fast-Acting Alzheimer's Therapy Excites Researchers • Too Much Sugar May Increase Alzheimer’s Risk • Beta Carotene May Slow Memory Loss • Promising Alzheimer’s Discovery Reported • Misconceptions About Alzheimer's Vary Among Races • Mediterranean Diet May Extend Alzheimer’s Patients’ Lives • Researchers Link Smoking To Dementia • Caffeine May Keep Dementia At Bay In Women • Alzheimer’s Drug Seen As “Safe, Effective” • Researchers “A Step Closer” To Alzheimer’s Cure • FDA Approves Alzheimer’s Patch • Scientists Raise Hopes For Alzheimer's Vaccine • Researchers Hopeful About New Alzheimer’s Therapy • Blood Pressure Drugs May Provide Alzheimer’s Protection • Progress Toward Early Alzheimer's Diagnosis Reported • Alzheimer's Cases Up 10% In 5 Years • Loneliness Linked to Dementia • Gene Changes Identified in Alzheimer's • Mental Exercise May Help Seniors • Rote Learning Improves Memory in Seniors • Vegetables May Slow Memory Loss • Cabernet Sauvignon May Reduce Alzheimer's Risk • Fruit Juice May Reduce Alzheimer's Risk • Skin Test May Detect Alzheimer's Disease • Exercise May Prevent Dementia-Like Illnesses • An Apple A Day May Improve Memory • New Drug Reverses Alzheimer's Damage, Australian Researchers Report • Diabetes Drug May Help Treat Alzheimer's • For Women, Weight Loss May Precede Dementia • Researchers "Closer" To Preventing Alzheimer's • Statins Help Memory in Older Women • Study Links Healthy Diet To Reduced Alzheimer's Risk • Tea May Help Combat Alzheimer's • Education May Accelerate Alzheimer's Effects • Alzheimer's Found to be Mostly Genetic • Exercise May Reduce Risk of Dementia in Older People • Researchers Find DNA Link to Alzheimer's • Brain Scan, Fluid Analysis May Help Predict Alzheimer's • Eating Fish Associated With Slower Cognitive Decline • Word Recall An Alzheimer' s Tip-Off? • Interrupted Alzheimer's Trial Produced Promising Results • Gene Therapy May Offer Hope For Alzheimer's Patients • Alzheimer's Researchers Reverse Memory Loss in Mice • Alzheimer's Disease Reveals Itself Earlier, Study Finds

Researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center believe they have made an important advance in the battle against Alzheimer's disease.

The researchers say they have identified naturally occurring antibodies in human blood that may help to defend against Alzheimer's as well as other neurodegenerative diseases.

The search for an effective Alzheimer's treatment becomes more urgent with each passing year.

More than 26 million people worldwide are estimated to be living with Alzheimer’s disease in 2006, according to a study led by researchers at the Johns Hopkins Bloomberg School of Public Health.

That number is expected to quadruple by 2050 as the baby boom generation ages. By 2050, 43 percent of those with Alzheimer’s disease will need high-level care, equivalent to that of a nursing home.

The newly found antibodies selectively target aggregates of beta amyloid proteins called "oligomers" that are toxic to brain cells, while ignoring the benign single-molecule forms of the same proteins.

The existence of such antibodies was predicted by animal studies, but they were never previously demonstrated to be present in substantial quantities in blood from normal humans.

Lead researcher Dr. Norman Relkin, a behavioral neurologist and neuroscientist at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, said his team has been testing an antibody-based immunotherapy called Intravenous Immunoglobulin (IVIG) as a potential new treatment for Alzheimer's.

IVIG is made from the blood of healthy donors and was previously reported to contain small quantities of antibodies against beta amyloid.

“The effects of IVIG in lowering beta amyloid levels in Alzheimer’s patients in our Phase I clinical trial were much more profound than we expected,” Relkin said. “We couldn't readily explain this based on the low levels of anti-amyloid antibodies known to be present in IVIG. We suspected there might be another, unseen player.”

Relkin presented the findings this week at a conference in Washington, DC. He is director of the Memory Disorders Program at NewYork-Presbyterian/Weill Cornell and associate professor of clinical neurology at Weill Cornell Medical College.

NewYork-Presbyterian/Weill Cornell is currently leading a six-month Phase II study of IVIG in 24 patients with mild and moderate Alzheimer's disease, which is planned to be complete later this year. While this study may provide a signal of the effect of IVIG therapy to clinical outcomes, further investigation in larger controlled and longer-term trials will be needed to definitively demonstrate whether IVIG is useful in treating Alzheimer's.

Still, this discovery substantially boosts understanding of Alzheimer's and other neurodegenerative illnesses, the experts say.

Global Epidemic

The findings were presented at the Second Alzheimer’s Association International Conference on Prevention of Dementia held in Washington, D.C. and are published in the Association’s journal, Alzheimer’s & Dementia.

Researchers at the conference warned that global health care systems would be overrun with Alzheimer's sufferers if an effective treatment is not developed.

“We face a looming global epidemic of Alzheimer’s disease as the world’s population ages,” said the study’s lead author, Ron Brookmeyer, PhD, professor in Biostatistics and chair of the Master of Public Health Program at the Bloomberg School of Public Health.

“By 2050, 1 in 85 persons worldwide will have Alzheimer’s disease. However, if we can make even modest advances in preventing Alzheimer’s disease or delay its progression, we could have a huge global public health impact.”

According to Brookmeyer and his co-authors, interventions that could delay the onset of Alzheimer’s disease by as little as one year would reduce prevalence of the disease by 12 million fewer cases in 2050.

A similar delay in both the onset and progression of Alzheimer’s disease would result in a smaller overall reduction of 9.2 million cases by 2050, because slower disease progression would mean more people surviving with early-stage disease symptoms. However, nearly all of that decline would be attributable to decreases in those needing costly late-stage disease treatment in 2050.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Back to the top |